Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sienna Biopharmaceuticals

OTCPK:SNNA.Q
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNNA.Q
OTCPK
$1M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Sienna Biopharmaceuticals has significant price volatility in the past 3 months.
SNNA.Q Share Price and Events
7 Day Returns
-60.4%
OTCPK:SNNA.Q
1.8%
US Pharmaceuticals
1.5%
US Market
1 Year Returns
-98.5%
OTCPK:SNNA.Q
11.8%
US Pharmaceuticals
27.6%
US Market
SNNA.Q Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sienna Biopharmaceuticals (SNNA.Q) -60.4% -77.7% -74.9% -98.5% - -
US Pharmaceuticals 1.8% 6.7% 10% 11.8% 23.1% 14.6%
US Market 1.5% 2.5% 6.2% 27.6% 38.3% 48.1%
1 Year Return vs Industry and Market
  • SNNA.Q underperformed the Pharmaceuticals industry which returned 11.8% over the past year.
  • SNNA.Q underperformed the Market in United States of America which returned 27.6% over the past year.
Price Volatility
SNNA.Q
Industry
5yr Volatility vs Market

SNNA.Q Value

 Is Sienna Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sienna Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $0.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sienna Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sienna Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:SNNA.Q PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-1.80
OTCPK:SNNA.Q Share Price ** OTCPK (2019-12-19) in USD $0.04
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 30 Publicly-Listed Pharmaceuticals Companies 17.76x
United States of America Market PE Ratio Median Figure of 2,927 Publicly-Listed Companies 18.85x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sienna Biopharmaceuticals.

OTCPK:SNNA.Q PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:SNNA.Q Share Price ÷ EPS (both in USD)

= 0.04 ÷ -1.80

-0.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sienna Biopharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Sienna Biopharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sienna Biopharmaceuticals's expected growth come at a high price?
Raw Data
OTCPK:SNNA.Q PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 1.63x
United States of America Market PEG Ratio Median Figure of 2,041 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sienna Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sienna Biopharmaceuticals's assets?
Raw Data
OTCPK:SNNA.Q PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.75
OTCPK:SNNA.Q Share Price * OTCPK (2019-12-19) in USD $0.04
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 177 Publicly-Listed Pharmaceuticals Companies 3.04x
United States of America Market PB Ratio Median Figure of 5,096 Publicly-Listed Companies 1.8x
OTCPK:SNNA.Q PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:SNNA.Q Share Price ÷ Book Value per Share (both in USD)

= 0.04 ÷ 0.75

0.05x

* Primary Listing of Sienna Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sienna Biopharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Sienna Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sienna Biopharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SNNA.Q Future Performance

 How is Sienna Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sienna Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.5%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sienna Biopharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Sienna Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sienna Biopharmaceuticals's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Sienna Biopharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:SNNA.Q Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:SNNA.Q Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:SNNA.Q Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 50 1
2022-12-31 0 1
2021-12-31 0 1
2020-12-31 0 1
2019-12-31 0 1
2019-12-20
OTCPK:SNNA.Q Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -55 -48
2019-06-30 -53 -61
2019-03-31 -60 -73
2018-12-31 -62 -73
2018-09-30 -60 -65
2018-06-30 -54 -65
2018-03-31 -49 -58
2017-12-31 -41 -51
2017-09-30 -32 -48
2017-06-30 -28 -35
2017-03-31 -21 -27
2016-12-31 -18 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sienna Biopharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Sienna Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:SNNA.Q Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Sienna Biopharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SNNA.Q Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-12-20
OTCPK:SNNA.Q Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -1.80
2019-06-30 -2.53
2019-03-31 -3.38
2018-12-31 -3.59
2018-09-30 -3.22
2018-06-30 -3.44
2018-03-31 -4.02
2017-12-31 -5.19
2017-09-30 -9.34
2017-06-30 -19.42
2017-03-31 -15.68
2016-12-31 -12.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sienna Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of SNNA.Q’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sienna Biopharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Sienna Biopharmaceuticals's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sienna Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sienna Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SNNA.Q Past Performance

  How has Sienna Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sienna Biopharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sienna Biopharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sienna Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sienna Biopharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sienna Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sienna Biopharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SNNA.Q Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -47.95 16.41 26.77
2019-06-30 -60.78 16.52 35.10
2019-03-31 -72.75 18.56 45.11
2018-12-31 -73.47 18.61 51.59
2018-09-30 -65.33 19.04 50.28
2018-06-30 -64.92 17.72 47.53
2018-03-31 -57.54 16.41 38.55
2017-12-31 -50.55 15.10 30.48
2017-09-30 -47.64 12.24 24.85
2017-06-30 -35.37 10.00 18.20
2017-03-31 -27.43 8.69 13.98
2016-12-31 -21.16 8.00 10.99
2015-12-31 -11.29 4.60 2.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sienna Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sienna Biopharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sienna Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sienna Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sienna Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SNNA.Q Health

 How is Sienna Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sienna Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sienna Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sienna Biopharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sienna Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sienna Biopharmaceuticals Company Filings, last reported 2 months ago.

OTCPK:SNNA.Q Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 23.10 10.10 11.33
2019-06-30 26.98 29.47 49.21
2019-03-31 33.29 29.24 57.17
2018-12-31 26.58 30.13 48.53
2018-09-30 44.93 29.98 63.98
2018-06-30 55.53 29.90 74.89
2018-03-31 76.42 0.00 60.01
2017-12-31 91.20 0.00 74.47
2017-09-30 96.40 0.00 88.60
2017-06-30 44.00 0.00 31.72
2017-03-31 13.56 3.29 6.84
2016-12-31 22.12 0.00 9.09
2015-12-31 4.05 0.00 4.96
  • Sienna Biopharmaceuticals's level of debt (41.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if Sienna Biopharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sienna Biopharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Sienna Biopharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.2% each year.
X
Financial health checks
We assess Sienna Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sienna Biopharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SNNA.Q Dividends

 What is Sienna Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sienna Biopharmaceuticals dividends.
If you bought $2,000 of Sienna Biopharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sienna Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sienna Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:SNNA.Q Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1962 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:SNNA.Q Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-12-20

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sienna Biopharmaceuticals has not reported any payouts.
  • Unable to verify if Sienna Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sienna Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sienna Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sienna Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sienna Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sienna Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SNNA.Q Management

 What is the CEO of Sienna Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frederick Beddingfield
COMPENSATION $2,616,799
AGE 54
TENURE AS CEO 3.9 years
CEO Bio

Dr. Frederick C. Beddingfield, III, M.D., Ph.D. has been the Chief Executive Officer and President of Sienna Labs, Inc. since January 2016. Dr. Beddingfield has been the Chief Medical Officer of Kythera Biopharmaceuticals, Inc. since March 23, 2013. Dr. Beddingfield joined KYTHERA from Allergan, Inc., which he joined in 2003. He has served as Vice President and Global Therapeutic Area Head of Dermatology and Aesthetics since August 2005, as well as Chief Medical Officer of Allergan Medical from August 2008 through December 2010. Since 2001, Dr. Beddingfield has also served as an Assistant Clinical Professor of Medicine, Division of Dermatology, at the David Geffen School of Medicine at UCLA. He has been the Director of Sienna Labs, Inc. since August 2015. He received his M.D. from the University of North Carolina at Chapel Hill and a Bachelor of Arts in Psychology from North Carolina State University in Raleigh, N.C.  In addition, Dr. Beddingfield holds a Ph.D. in Policy Analysis from the RAND Graduate School of Policy Studies. He is a Board-Certified Dermatologist.

CEO Compensation
  • Frederick's compensation has increased whilst company is loss making.
  • Frederick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sienna Biopharmaceuticals management team in years:

2.8
Average Tenure
49
Average Age
  • The tenure for the Sienna Biopharmaceuticals management team is about average.
Management Team

Frederick Beddingfield

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
3.9 yrs

Timothy Andrews

TITLE
General Counsel & Corporate Secretary
COMPENSATION
$1M
AGE
40
TENURE
3.2 yrs

Alex Azoy

TITLE
CFO & Controller
AGE
43
TENURE
0.7 yrs

Silvio Traversa

TITLE
Chief Scientific Officer
AGE
49
TENURE
3 yrs

Sean Andrews

TITLE
Vice President of Investor Relations
TENURE
2.6 yrs

Ted Schwartz

TITLE
Head of Global Strategic Marketing
AGE
58
TENURE
3.9 yrs

Michael Attar

TITLE
VP & Head of Corporate Development
TENURE
1.1 yrs

Paul Lizzul

TITLE
Chief Medical Officer
COMPENSATION
$401K
AGE
44
TENURE
3.9 yrs

Caroline Van Hove

TITLE
Chief Commercial Officer
TENURE
1.8 yrs

David E. Pyott

TITLE
Strategic Advisor to the Board and CEO
AGE
66
TENURE
2.4 yrs
Board of Directors Tenure

Average tenure and age of the Sienna Biopharmaceuticals board of directors in years:

3.5
Average Tenure
55.5
Average Age
  • The tenure for the Sienna Biopharmaceuticals board of directors is about average.
Board of Directors

Keith Leonard

TITLE
Chairman
COMPENSATION
$172K
AGE
57
TENURE
3.9 yrs

Frederick Beddingfield

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
4.3 yrs

Dennis Fenton

TITLE
Independent Director
COMPENSATION
$148K
AGE
67
TENURE
3.2 yrs

Jim Hindman

TITLE
Independent Director
COMPENSATION
$213K
AGE
58
TENURE
1.3 yrs

Todd Harris

TITLE
Director
COMPENSATION
$265K
AGE
40
TENURE
9.9 yrs

Bob More

TITLE
Independent Director
COMPENSATION
$139K
AGE
51
TENURE
6.6 yrs

Kristina Burow

TITLE
Independent Director
COMPENSATION
$138K
AGE
46
TENURE
4.2 yrs

Matthew Avram

TITLE
Member of Corporate Advisory Board
TENURE
2 yrs

Diane Berson

TITLE
Member of Corporate Advisory Board
AGE
60
TENURE
2 yrs

Robert Bissonnette

TITLE
Member of Corporate Advisory Board
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Feb 19 Buy Arch Venture Partners, L.P. Company 22. Feb 19 22. Feb 19 2,165,800 $2.50 $5,414,500
26. Feb 19 Buy Keith Leonard Individual 22. Feb 19 22. Feb 19 100,000 $2.50 $250,000
26. Feb 19 Buy Frederick Beddingfield Individual 22. Feb 19 22. Feb 19 40,000 $2.50 $100,000
26. Feb 19 Buy Robert More Individual 22. Feb 19 22. Feb 19 100,000 $2.50 $250,000
X
Management checks
We assess Sienna Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sienna Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SNNA.Q News

Simply Wall St News

SNNA.Q Company Info

Description

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company’s lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On September 16, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Details
Name: Sienna Biopharmaceuticals, Inc.
SNNA.Q
Exchange: OTCPK
Founded: 2010
$1,230,596
30,764,904
Website: http://www.siennabio.com
Address: Sienna Biopharmaceuticals, Inc.
30699 Russell Ranch Road,
Suite 140,
Westlake Village,
California, 91362,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK SNNA.Q Common Stock Pink Sheets LLC US USD 27. Jul 2017
DB 1AR Common Stock Deutsche Boerse AG DE EUR 27. Jul 2017
Number of employees
Current staff
Staff numbers
13
Sienna Biopharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/20 00:41
End of day share price update: 2019/12/19 00:00
Last estimates confirmation: 2019/09/17
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.